Send to:

Choose Destination
See comment in PubMed Commons below
Adv Nutr. 2010 Nov;1(1):3-7. doi: 10.3945/an.110.1003. Epub 2010 Nov 16.

(n-3) Fatty Acids: Clinical Trials in People with Type 2 Diabetes.

Author information

  • 1Food Science and Human Nutrition, Iowa State University, Ames, IA 50011.


Recent human clinical trials of the effects of (n-3) fatty acids on participants with type 2 diabetes (T2D) were reviewed, focusing on 11 clinical trials conducted within the past 4 y, and subsequent to a Cochrane Database meta-analysis of this topic. Doses of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in these studies were mostly in the range of ∼2 g/d provided for 6 wk to 6 mo. Summarizing across these studies, there were no changes in fasting glucose or insulin compared with baseline or placebo. (n-3) Fatty acids generally decreased serum triglycerides but had varying effects on serum cholesterol, LDL cholesterol, and HDL cholesterol. A few studies indicated beneficial effects of (n-3) fatty acids on arterial blood flow. The effects of EPA and/or DHA have not yet been studied in clinical trials in participants at risk for T2D; the prevention or exacerbation of T2D by fish oil or EPA and DHA supplements of amounts >0.5 g/d deserves study. The prevention of adverse vascular effects of T2D by (n-3) fatty acids may be a promising direction for further study.

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk